Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Niamh Coleman


Niamh Coleman

University of Texas MD Anderson Cancer Center (MDACC)

United States of America

Niamh Coleman, MBBCH BAO PhD, is a fellow in the Department of Investigational Cancer Therapeutics (Phase I Program) Oncology at the University of Texas MD Anderson Cancer Center (MDACC). She undertook her medical oncology training in Ireland and completed Higher Specialist Training in Medical Oncology in Ireland in July 2017. Dr. Coleman pursued an extended period of clinical research, including a fellowship in phase I drug development and a translational PhD at the Royal Marsden Hospital and the Institute of Cancer Research, London, England.

Dr. Coleman has extensive experience in translational cancer research with a focus on resistance mechanisms and druggable kinases. Dr. Coleman’s main research interests have been focused on the clinical and translational development of novel inhibitors against receptor tyrosine kinases, such as MET and EGFR, and signaling pathways such as AKT/ PI3K/ MTOR. Dr. Coleman has expertise in the design, development and conduct of hypothesis-testing, biomarker-driven early phase clinical trials, well as the assessment of circulating tumour DNA (ctDNA) while on novel systemic therapies.

Last update: September 2021

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.